Frontiers in Veterinary Science ( IF 2.6 ) Pub Date : 2021-01-11 , DOI: 10.3389/fvets.2021.623800 Guillermo Valdivia 1, 2 , Ángela Alonso-Diez 1, 2 , Dolores Pérez-Alenza 1, 2 , Laura Peña 1, 2
Canine mammary tumors (CMTs) are the most common neoplasm in intact female dogs. Canine mammary cancer (CMC) represents 50% of CMTs, and besides surgery, which is the elective treatment, additional targeted and non-targeted therapies could offer benefits in terms of survival to these patients. Also, CMC is considered a good spontaneous intermediate animal model for the research of human breast cancer (HBC), and therefore, the study of new treatments for CMC is a promising field in comparative oncology. Dogs with CMC have a comparable disease, an intact immune system, and a much shorter life span, which allows the achievement of results in a relatively short time. Besides conventional chemotherapy, innovative therapies have a large niche of opportunities. In this article, a comprehensive review of the current research in adjuvant therapies for CMC is conducted to gather available information and evaluate the perspectives. Firstly, updates are provided on the clinical–pathological approach and the use of conventional therapies, to delve later into precision therapies against therapeutic targets such as hormone receptors, tyrosine kinase receptors,
中文翻译:
犬乳腺癌从传统治疗到精准治疗:综合综述
犬乳腺肿瘤(CMT)是完整雌性犬中最常见的肿瘤。犬乳腺癌 (CMC) 占 CMT 的 50%,除了作为选择性治疗的手术之外,额外的靶向和非靶向治疗可以为这些患者带来生存方面的益处。此外,CMC被认为是研究人类乳腺癌(HBC)的良好自发中间动物模型,因此,CMC新疗法的研究是比较肿瘤学中一个有前途的领域。患有 CMC 的狗有类似的疾病、完整的免疫系统和更短的寿命,这使得在相对较短的时间内取得成果。除了传统化疗之外,创新疗法还有很大的机会。在本文中,对 CMC 辅助治疗的当前研究进行了全面回顾,以收集可用信息并评估观点。首先,提供了临床病理学方法和常规疗法使用的最新信息,以便随后深入研究针对治疗靶点的精准疗法,例如激素受体、酪氨酸激酶受体、